

Clinical trials of mTOR inhibitor for advanced renal-cell carcinoma in all type of patients

TrialResults-center www.trialresultscenter.org

1 mTor inhibitor

Trial	Treatments	Patients	Trials design and methods
temsirolimus vs interferon alpha			
ARCC (Hudes) temsirolimus alone , 2007 [NCT00065468] n=209/207 follow-up:	25 mg of intravenoustemsirolimus weekly versus 3 million U of interferon alfa (with an increase to 18 millionU) subcutaneously three times weekly	patients with previously untreated, poor-prognosis metastatic renal-cell carcinoma	
everolimus vs placebo			
RECORD-1 , 2008 [NCT00410124] n=272/138 follow-up:	everolimus 10 mg once daily versus placebo	Patients with metastatic renal cell carcinoma which had progressed on sunitinib, sorafenib, or both	
temsirolimus vs sorafenib			
INTORSECT , 2014 [NCT00474786] n=259/253 follow-up:	temsirolimus 25 mg once weekly by intravenous (IV) infusion versus sorafenib 400 mg PO twice daily	Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib	
everolimus vs sunitinib			
RECORD 3 , 2014 [NCT00903175] n=238/233 follow-up:	everolimus versus sunitinib	patients with metastatic renal cell carcinoma	Cross over

References

ARCC (Hudes) temsirolimus alone, 2007:

Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. *N Engl J Med* 2007;356:2271-81 [[17538086](#)]

RECORD-1, 2008:

Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grnwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Leblwohl D, Ravaud A Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. *Lancet* 2008;372:449-56 [[18653228](#)]

INTORSECT, 2014:

Hutson TE, Escudier B, Esteban E, Bjarnason GA, Lim HY, Pittman KB, Senico P, Niethammer A, Lu DR, Hariharan S, Motzer RJ Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. *J Clin Oncol* 2014;32:760-7 [[24297950](#)]

RECORD 3, 2014:

Motzer RJ, Barrios CH, Kim TM, Falcon S, Cosgriff T, Harker WG, Srimuninnimit V, Pittman K, Sabbatini R, Rha SY, Flaig TW, Page R, Bavbek S, Beck JT, Patel P, Cheung FY, Yadav S, Schiff EM, Wang X, Niolat J, Sellami D, Anak O, Knox JJ Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma. *J Clin Oncol* 2014;32:2765-72 [25049330]

Entry terms: everolimus eluting stent, XIENCE V, Guidant XIENCE V, Abbott XIENCE V, XIENCE 5, SDZ RAD, SDZ-RAD, 40-O-(2-hydroxyethyl)-rapamycin, RAD 001, RAD001, Afinitor, Certican,

2 About TrialResults-center.org

TrialResults-center is an innovative knowledge database that collects the results of RCTs and provides dynamic interactive systematic reviews and meta-analysis in the field of all major heart and vessels diseases.

The TrialResults-center database provides a unique view of the treatment efficacy based on all data provided directly from clinical trial results, offering a valuable alternative to personal bibliographic search, published meta-analysis, etc. Furthermore, it would allow comparing easily the various concurrent therapeutic for the same clinical condition.

Rigorous meta-analysis method is used to populate TrialResults-center: widespread search of published and non published trials, study selection using pre-specified criteria, data extraction using standard form.

TrialResults-center is continually updated on a weekly basis. We continually search all new results (whatever their publication channel) and these news results are immediately added to the database with a maximum of 1 week.

TrialResults-center is non-profit and self-funded.